Ovarian cancer risk and use of phenolphthalein-containing laxatives

Pharmacoepidemiology and Drug Safety

Volumn 13, Issue 1, 2004, Pages 35-39

  Cooper, Glinda S ^a   Longnecker, Matthew P ^a   Peters, Ruth K ^b  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Laxative; Ovarian cancer; Phenolphthalein

Indexed keywords

LAXATIVE; NON PRESCRIPTION DRUG; PHENOLPHTHALEIN;

ADULT; AFRICAN AMERICAN; AGE; ARTICLE; CANCER REGISTRY; CANCER RISK; CASE CONTROL STUDY; CAUCASIAN; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; ETHNOLOGY; FEMALE; HISPANIC; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; OVARY CANCER; POPULATION RESEARCH; PRIORITY JOURNAL; RACE DIFFERENCE; RISK ASSESSMENT; UNITED STATES;

ADULT; CASE-CONTROL STUDIES; CATHARTICS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PHENOLPHTHALEIN; RISK FACTORS;

EID: 0742324805     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.824     Document Type: Article

References (16)

1. Food and Drug Administration. Laxative drug products for over-the-counter human use. Fed Regist 1999; 64: 4535-4540.
2. Dunnick JK, Hailey JR. Phenolphthalein exposure causes multiple carcinogenic effects in experimental model systems. Cancer Res 1996; 56: 4922-4926.
3. National Toxicology Program. NTP technical report on the toxicology and carcinogenesis studies of phenolphthalein (CAS no. 77-09-8) in F344/N rats and B6C3F1R mice (feed studies). National Toxicology Program Technical Report Series. 1996; 465: 1-348. (NIN Publication Number 97-3990, available from the National Technical Information Service, Springfield, VA).
4. WHO Pharmaceuticals Newsletter. Laxatives containing phenolphthalein - voluntary withdrawal. 1998; 1-2: 4-15.
5. De Smet PH, Wagenaar HW. Weight reduction preparations from Thailand: unexpected complication for the traveler. Ned Tijdschr Geneeskd 1988; 142: 2798-2800.
6. Cozen W, Peters RK, Reichardt JKV, et al. Galactose-1-phosphate uridyl transferase (GALT) genotype and phenotype, galactose consumption and the risk of borderline and invasive ovarian cancer. Cancer Causes Control 2002; 13: 113-120.
7. Physicians' Desk Reference for Nonprescription Drugs and Dietary Supplements. 11th edition. Medical Economics Company, Inc: Montvale, NJ, 1990.
8. Cooper GS, Longnecker MP, Sandler DP, Ness RB. Risk of ovarian cancer in relation to use of phenolphthalein-containing laxatives. Br J Cancer 2000; 83: 404-406.
9. Coogan PF, Rosenberg L, Palmer JR, et al. Phenolphthalein laxatives and risk of cancer. J Natl Cancer Inst 2000; 92: 1943-1944.
10. Bo-Linn GW, Santa Ana CA, Morawski SG, Fordtran JS. Purging and caloric absorption in bulimic patients and normal women. Ann Intern Med 1983; 99: 14-17.
11. Bytzer P, Stokholm M, Andersen I, Klitgaard NA, Schaffalitzky de Muckadell OB. Prevalence of surreptitious laxative abuse in patients with diarrhoea of uncertain origin: a cost benefit analysis of a screening procedure. Gut 1989; 30: 1379-1384.
12. Cramer DW, Hutchinson GB, Welch WR. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst 1983; 71: 717-721.
13. Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 1998; 90: 1774-1786.
14. Ravdin PM, van Beurden M, Jordan VC. Estrogenic effects of phenolphthalein on human breast cancer cells in vitro. Breast Cancer Res Treat 1987; 9: 151-154.
15. Garner CE, Matthews HB, Burka LT. Phenolphthalein metabolite inhibits catechol-o-methyltranseferase-mediated metabolism of catechol estogens: a possible mechanism for carcinogenicity. Toxic Applied Pharmacol 2000; 162: 124-131.
16. Scully RE. Classification of human ovarian tumors. Environ Health Perspect 1987; 73: 15-24.